Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis

References

• Longo V, Brunetti O, D’Oronzo S, Ostuni C, Gatti P, Silvestris F. Bone metastases in hepatocellular carcinoma: an emerging issue. Cancer Metastasis Rev. 2014;33(1):333–342. doi:10.1007/s10555-013-9454-4
   PubMed Web of Science ®Google Scholar
• Kanda M, Tateishi R, Yoshida H, et al. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int. 2008;28(9):1256–1263. doi:10.1111/j.1478-3231.2008.01864.x
   PubMed Web of Science ®Google Scholar
• Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer. 2012;1(3–4):144–158. doi:10.1159/000343828
   PubMed Web of Science ®Google Scholar
• Katyal S, Oliver JH, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216(3):698–703. doi:10.1148/radiology.216.3.r00se24698
   PubMed Web of Science ®Google Scholar
• Shuto T, Hirohashi K, Kubo S, et al. Treatment of adrenal metastases after hepatic resection of a hepatocellular carcinoma. Dig Surg. 2001;18(4):294–297. doi:10.1159/000050155
   PubMed Web of Science ®Google Scholar
• Attili VS, Babu KG, Lokanatha D, Bapsy PP, Ramachandra C, Rajshekar H. Bone metastasis in hepatocellular carcinoma: need for reappraisal of treatment. J Cancer Res Ther. 2008;4(2):93–94. doi:10.4103/0973-1482.42257
   PubMed Web of Science ®Google Scholar
• Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol. 2005;20(11):1781–1787. doi:10.1111/j.1440-1746.2005.03919.x
   PubMed Web of Science ®Google Scholar
• Santini D, Pantano F, Riccardi F, et al. Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. PLoS One. 2014;9(8):e105268. doi:10.1371/journal.pone.0105268
   PubMed Web of Science ®Google Scholar
• Lu Y, Hu JG, Lin XJ, Li XG. Bone metastases from hepatocellular carcinoma: clinical features and prognostic factors. Hepatobiliary Pancreat Dis Int. 2017;16(5):499–505. doi:10.1016/S1499-3872(16)60173-X
   PubMed Web of Science ®Google Scholar
• Lee MH, Lee SH, Kim ES, Eoh W, Chung SS, Lee CS. Survival-related factors of spinal metastasis with hepatocellular carcinoma in current surgical treatment modalities: a single institute experience. J Korean Neurosurg Soc. 2015;58(5):448–453. doi:10.3340/jkns.2015.58.5.448
   PubMed Web of Science ®Google Scholar
• Guo X, Xu Y, Wang X, et al. Advanced hepatocellular carcinoma with bone metastases: prevalence, associated factors, and survival estimation. Med Sci Monit. 2019;10(25):1105–1112. doi:10.12659/MSM.913470
   Google Scholar
• He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer. 2009;115(12):2710–2720. doi:10.1002/cncr.24300
   PubMed Web of Science ®Google Scholar
• Fukutomi M, Yokota M, Chuman H, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2001;13(9):1083–1088. doi:10.1097/00042737-200109000-00015
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Hu C, Yang J, Huang Z, et al. Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma. BMC Cancer. 2020;20(1):494. doi:10.1186/s12885-020-06995-y
   PubMed Web of Science ®Google Scholar
• Kim SU, Kim DY, Park JY, et al. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol. 2008;134(12):1377–1384. doi:10.1007/s00432-008-0410-6
   PubMed Web of Science ®Google Scholar
• Bhatia R, Ravulapati S, Befeler A, Dombrowski J, Gadani S, Poddar N. Hepatocellular carcinoma with bone metastases: incidence, prognostic significance, and management-single-center experience. J Gastrointest Cancer. 2017;48(4):321–325. doi:10.1007/s12029-017-9998-6
   PubMedGoogle Scholar
• Kanishi D. 99mTc-MDP accumulation mechanisms in bone. Oral Surg Oral Med Oral Pathol. 1993;75(2):239–246. doi:10.1016/0030-4220(93)90100-I
   PubMedGoogle Scholar
• Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001;45(1):53–64.
   PubMedGoogle Scholar
• Ho CL, Chen S, Cheng TK, Leung YL. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. Radiology. 2011;258(2):515–523. doi:10.1148/radiol.10100672
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004;39(10):961–968. doi:10.1007/s00535-004-1427-5
   PubMed Web of Science ®Google Scholar
• Harding JJ, Abu-Zeinah G, Chou JF, et al. Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma. J Natl Compr Canc Netw. 2018;16(1):50–58. doi:10.6004/jnccn.2017.7024
   PubMed Web of Science ®Google Scholar
• Kim S, Choi Y, Kwak DW, et al. Prognostic factors in hepatocellular carcinoma patients with bone metastases. Radiat Oncol J. 2019;37(3):207–214. doi:10.3857/roj.2019.00136
   PubMed Web of Science ®Google Scholar
• Chang YS, Huang JS, Yen CL, et al. Body mass index above 24 is beneficial for the 6-month survival rate in hepatocellular carcinoma patients with extrahepatic metastases. Asia Pac J Clin Nutr. 2017;26(4):637–641. doi:10.6133/apjcn.062016.03
   PubMed Web of Science ®Google Scholar
• Seo HJ, Kim GM, Kim JH, Kang WJ, Choi HJ. 18F-FDG PET/CT in hepatocellular carcinoma: detection of bone metastasis and prediction of prognosis. Nucl Med Commun. 2015;36(3):226–233. doi:10.1097/MNM.0000000000000246
   PubMed Web of Science ®Google Scholar
• Zhang L, Niu H, Yang P, et al. Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients. BMC Cancer. 2021;21(1):161. doi:10.1186/s12885-021-07808-6
   PubMed Web of Science ®Google Scholar
• Xiang ZL, Zeng ZC, Tang ZY, et al. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer. 2009;9:176. doi:10.1186/1471-2407-9-176
   PubMed Web of Science ®Google Scholar
• Xiang ZL, Zhao XM, Zhang L, et al. MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma. Oncotarget. 2016;7(52):87246–87256. doi:10.18632/oncotarget.13531
   PubMedGoogle Scholar
• Zhang L, Niu H, Ma J, et al. The molecular mechanism of LncRNA34a-mediated regulation of bone metastasis in hepatocellular carcinoma. Mol Cancer. 2019;18(1):120. doi:10.1186/s12943-019-1044-9
   PubMedGoogle Scholar
• Xiang ZL, Zeng ZC, Tang ZY, et al. Potential prognostic biomarkers for bone metastasis from hepatocellular carcinoma. Oncologist. 2011;16(7):1028–1039. doi:10.1634/theoncologist.2010-0358
   PubMed Web of Science ®Google Scholar
• Iguchi H, Yokota M, Fukutomi M, et al. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2002;21(3):309–313.
   PubMed Web of Science ®Google Scholar
• Jahanban-Esfahlan R, Seidi K, Manjili MH, Jahanban-Esfahlan A, Javaheri T, Zare P. Tumor cell dormancy: threat or opportunity in the fight against cancer. Cancers. 2019;11(8):1207. doi:10.3390/cancers11081207
   PubMed Web of Science ®Google Scholar
• Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6(10):2609–2617. doi:10.1158/1535-7163.MCT-07-0234
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhou H, Dunstan CR, Sutherland RL, Seibel MJ. The role of the bone microenvironment in skeletal metastasis. J Bone Oncol. 2013;2(1):47–57. doi:10.1016/j.jbo.2012.11.002
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–1664. doi:10.1056/NEJMra030831
   PubMed Web of Science ®Google Scholar
• Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis. 2007;24(8):599–608. doi:10.1007/s10585-007-9112-8
   PubMed Web of Science ®Google Scholar
• Yuan X, Zhuang M, Zhu X, et al. Emerging perspectives of bone metastasis in hepatocellular carcinoma. Front Oncol. 2022;12:943866. doi:10.3389/fonc.2022.943866
   PubMedGoogle Scholar
• Esposito M, Guise T, Kang Y. The biology of bone metastasis. Cold Spring Harb Perspect Med. 2018;8(6):a031252. doi:10.1101/cshperspect.a031252
   PubMed Web of Science ®Google Scholar
• Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int. 2005;25(2):261–265. doi:10.1111/j.1478-3231.2005.01094.x
   PubMed Web of Science ®Google Scholar
• Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423–1436. doi:10.1200/JCO.2006.09.5281
   PubMed Web of Science ®Google Scholar
• Choi C, Seong J. Predictive factors of palliative radiotherapy response and survival in patients with spinal metastases from hepatocellular carcinoma. Gut Liver. 2015;9(1):94–102. doi:10.5009/gnl14009
   PubMed Web of Science ®Google Scholar
• Zeng KL, Tseng CL, Soliman H, Weiss Y, Sahgal A, Myrehaug S. Stereotactic Body Radiotherapy (SBRT) for oligometastatic spine metastases: an overview. Front Oncol. 2019;9:337. doi:10.3389/fonc.2019.00337
   PubMed Web of Science ®Google Scholar
• Kim TH, Park S, Rim CH, Choi C, Seong J. Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma. J Cancer Res Clin Oncol. 2021;147(9):2693–2700. doi:10.1007/s00432-021-03553-2
   PubMed Web of Science ®Google Scholar
• Carrafiello G, Laganà D, Ianniello A, et al. Radiofrequency thermal ablation for pain control in patients with single painful bone metastasis from hepatocellular carcinoma. Eur J Radiol. 2009;71(2):363–368. doi:10.1016/j.ejrad.2008.04.019
   PubMed Web of Science ®Google Scholar
• Uemura A, Fujimoto H, Yasuda S, et al. Transcatheter arterial embolization for bone metastases from hepatocellular carcinoma. Eur Radiol. 2001;11(8):1457–1462. doi:10.1007/s003300000792
   PubMed Web of Science ®Google Scholar
• Ozer M, George A, Goksu SY, George TJ, Sahin I. The role of immune checkpoint blockade in the hepatocellular carcinoma: a review of clinical trials. Front Oncol. 2021;11:801379. doi:10.3389/fonc.2021.801379
   PubMed Web of Science ®Google Scholar
• Li JJ, Liang Q, Sun GC. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: a focus on epithelial-mesenchymal transition. J Integr Med. 2021;19(6):469–477. doi:10.1016/j.joim.2021.08.004
   PubMed Web of Science ®Google Scholar